Cencora Aktie News

U.S. drug distributor Cencora said on Monday it will take majority control of cancer care network OneOncology in a deal that values the business at $7.4 billion, as it moves to expand services for community oncology practices.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm. “W...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Europe, expanding its global network and strengthening the specialty logistics services it can deliver to pharmaceutical companies worldwide. As more specialty pharmaceuticals reach the market and the...

Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript

Cencora is rated a Buy, with a target price of $392, driven by strong fundamentals and sector leadership. COR's stable business model, high cash flows, low debt, and shareholder-friendly policies make it attractive for conservative, long-term investors. Recent earnings showed double-digit profit growth, robust revenue from specialty drugs, and high predictability, supporting management's optimi...

Cencora, Inc. ( COR ) Q4 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Robert Mauch - President, CEO & Director James Cleary - Executive VP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michae...

Cencora will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted profit for next year above Wall Street expectations.